Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leukemia, Lymphocytic, Acute: early-phase trial registry
1 of 3 indexed Leukemia, Lymphocytic, Acute trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 1 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Leukemia, Lymphocytic, Acute: 3 US clinical trials tracked, 1 recruiting.
Leukemia, Lymphocytic, Acute is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Sunesis Pharmaceuticals, running 1 of these trials.
Enrollment posture brief
Registry condition leukemia-lymphocytic-acute
OPEN 1 | RECR 33% | LATE 0 | EARLY 2 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Leukemia, Lymphocytic, Acute lists 1 open slots (33% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leukemia, Lymphocytic, Acute on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leukemia, Lymphocytic, Acute is recruiting below its size-band peers.
1 of 3 indexed trials (33.3%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation
Sumitomo Pharma America
NCT04988555
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
Sunesis Pharmaceuticals
NCT00246662
T-cell Minimal Residual Disease (MRD) Evaluation Using Flow Cytometric Analysis
Stanford University
NCT01078337
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Leukemia, Lymphocytic, Acute records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leukemia, Lymphocytic, Acute trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leukemia, Lymphocytic, Acute page
3 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 1 Leukemia, Lymphocytic, Acute trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Sunesis Pharmaceuticals sponsors the most Leukemia, Lymphocytic, Acute trials on record, review their full trial history before evaluating a specific study. See Sunesis Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukemia, Lymphocytic, Acute condition card totals 3 registered trials; most-linked intervention peripheral blood sampling; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.